Arovella Therapeutics (ALA) Corporate presentation summary
Event summary combining transcript, slides, and related documents.
Corporate presentation summary
6 Jul, 2026Investment highlights
U.S. FDA IND accepted for ALA-101, with phase 1 trials for CD19-positive blood cancers expected in FY2026.
Developing off-the-shelf iNKT cell therapies for blood and solid tumour cancers.
Proprietary, clinic-ready manufacturing process for CAR-iNKT cells established.
Strategic acquisitions and strong leadership with cell therapy expertise.
Financial overview
Market capitalisation of $88.24 million as of May 2026, with $16.6 million cash on hand at March 2026.
Share price ranged from $0.067 to $0.115 over the past year.
Major shareholders include UBS Nominees and Netwealth Investments.
Leadership and advisory network
Senior management and board have extensive drug development backgrounds.
Scientific and clinical advisory boards include experts from leading cancer centers globally.
Latest events from Arovella Therapeutics
- Off-the-shelf CAR-iNKT therapies advance to clinical trials, targeting broad oncology and autoimmune markets.ALA
Investor update - FDA IND accepted for ALA-101, advancing off-the-shelf iNKT cell therapies for cancer.ALACorporate presentation
- IND clearance and strong cash position support clinical trial launch for lead cell therapy.ALAQ3 2026 TU
- Net loss narrowed 14% to $7.5M as revenue rose 700% and cash reserves reached $20.9M.ALAH2 2025
- Cash reserves rose and clinical progress continued, with Phase 1 trials for ALA-101 expected in FY2025.ALAH2 2024
- Losses increased and revenue declined, but clinical and cash milestones were achieved.ALAH1 2026
- IND filed for ALA-101, Phase 1 trial set for 2026, $19.4M cash, and robust pipeline expansion.ALAQ2 2026 TU
- Strong cash position and clinical progress with ALA-101 and ALA-105 programs, plus new US patent.ALAQ1 2026 TU
- Clinical and strategic milestones achieved as CAR-iNKT pipeline advances toward trials.ALAAGM 2025